Comparing belinostat or pralatrexate with chemotherapy for PTCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding belinostat or pralatrexate to standard chemotherapy (CHOP) works better than CHOP alone for people newly diagnosed with peripheral T-cell lymphoma (PTCL). It aims to find a more effective first treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with a type of PTCL listed in the trial, like PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, or certain other subtypes.
- You have at least one tumor that can be measured by scans.
- You are physically well enough to be up and about most of the day (ECOG score 0-2).
- Your blood counts, liver function, and kidney function are within acceptable ranges (some flexibility if your lymphoma has affected these organs).
- You have not had prior treatment for PTCL and have not taken certain medications like belinostat or pralatrexate before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This Phase 2 trial tests how well Go-CHOP works as the first treatment for peripheral T-cell lymphoma (PTCL) subtypes. It aims to see whether adding golidocitinib to standard chemotherapy can control the lymphoma and improve outcomes.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.